Blocking ANXA1 with an antagonist (Boc1) or genetic deletion of ANXA1 eliminated the protective effects of CH against stroke damage, further confirming the role of ANXA1 in CH-mediated neuroprotection against stroke. The gene discussed is C4B; the disease is stroke disorder.